BACKGROUND: The incidence and associated risk factors for readmission after hepato-pancreato-biliary surgery are poorly characterized. The objective of the current study was to compare readmission after pancreatic vs hepatobiliary surgical procedures, as well as to identify potential factors associated with higher readmission within 30 days of discharge. STUDY DESIGN: Using Surveillance, Epidemiology and End Results-Medicare linked data from 1986-2005, we identified 9,957 individuals aged 66 years and older who underwent complex hepatic, biliary, or pancreatic procedures for cancer treatment and were eligible for analysis. In-hospital morbidity, mortality, and 30-day readmission were examined. RESULTS: Primary surgical treatment consisted of a pancreatic (46.7%), hepatic (50.0%), or biliary (3.4%) procedure. Mean patient age was 72.6 years and most patients were male (53.2%). The number of patients with multiple preoperative comorbidities increased over time (patients with Elixhauser's comorbidity score >13: 1986-1990, 47.0% vs 2001-2005, 62.9%; p < 0.001). Pancreatic operations had higher inpatient mortality vs hepatobiliary procedures (9.2% vs 7.3%; p < 0.001). Mean length of stay after pancreatic procedures was longer compared with hepatobiliary procedures (19.7 vs 10.3 days; p < 0.001). The proportion of patients readmitted after a pancreatic (1986-1990, 17.7%; 1991-1995, 16.1%; 1996-2000, 18.6%; 2001-2005, 19.6%; p = 0.15) or hepatobiliary (1986-1990, 14.3%; 1991-1995, 14.1%; 1996-2000, 15.2%; 2001-2005, 15.5%; p = 0.69) procedure did not change over time. Factors associated with increased risk of readmission included preoperative Elixhauser comorbidities >13 (odds ratio = 1.90) and prolonged index hospital stay ≥10 days (odds ratio = 1.54; both p < 0.05). During the readmission, additional morbidity and mortality were 46.5% and 8.0%, respectively. CONCLUSIONS: Although the incidence of readmission did not change across the time periods examined, readmission was higher among patients undergoing a pancreatic procedure vs a hepatobiliary procedure. Other factors associated with risk of readmission included number of patient comorbidities and prolonged hospital stay. Readmission was associated with additional short-term morbidity and mortality.
BACKGROUND: The incidence and associated risk factors for readmission after hepato-pancreato-biliary surgery are poorly characterized. The objective of the current study was to compare readmission after pancreatic vs hepatobiliary surgical procedures, as well as to identify potential factors associated with higher readmission within 30 days of discharge. STUDY DESIGN: Using Surveillance, Epidemiology and End Results-Medicare linked data from 1986-2005, we identified 9,957 individuals aged 66 years and older who underwent complex hepatic, biliary, or pancreatic procedures for cancer treatment and were eligible for analysis. In-hospital morbidity, mortality, and 30-day readmission were examined. RESULTS: Primary surgical treatment consisted of a pancreatic (46.7%), hepatic (50.0%), or biliary (3.4%) procedure. Mean patient age was 72.6 years and most patients were male (53.2%). The number of patients with multiple preoperative comorbidities increased over time (patients with Elixhauser's comorbidity score >13: 1986-1990, 47.0% vs 2001-2005, 62.9%; p < 0.001). Pancreatic operations had higher inpatient mortality vs hepatobiliary procedures (9.2% vs 7.3%; p < 0.001). Mean length of stay after pancreatic procedures was longer compared with hepatobiliary procedures (19.7 vs 10.3 days; p < 0.001). The proportion of patients readmitted after a pancreatic (1986-1990, 17.7%; 1991-1995, 16.1%; 1996-2000, 18.6%; 2001-2005, 19.6%; p = 0.15) or hepatobiliary (1986-1990, 14.3%; 1991-1995, 14.1%; 1996-2000, 15.2%; 2001-2005, 15.5%; p = 0.69) procedure did not change over time. Factors associated with increased risk of readmission included preoperative Elixhauser comorbidities >13 (odds ratio = 1.90) and prolonged index hospital stay ≥10 days (odds ratio = 1.54; both p < 0.05). During the readmission, additional morbidity and mortality were 46.5% and 8.0%, respectively. CONCLUSIONS: Although the incidence of readmission did not change across the time periods examined, readmission was higher among patients undergoing a pancreatic procedure vs a hepatobiliary procedure. Other factors associated with risk of readmission included number of patient comorbidities and prolonged hospital stay. Readmission was associated with additional short-term morbidity and mortality.
Authors: Eric B Schneider; Omar Hyder; Benjamin S Brooke; Jonathan Efron; John L Cameron; Barish H Edil; Richard D Schulick; Michael A Choti; Christopher L Wolfgang; Timothy M Pawlik Journal: J Am Coll Surg Date: 2012-01-29 Impact factor: 6.113
Authors: Anne O Lidor; Eric Schneider; Jodi Segal; Qilu Yu; Richard Feinberg; Albert W Wu Journal: J Gastrointest Surg Date: 2010-09-28 Impact factor: 3.452
Authors: G A Porter; P W Pisters; C Mansyur; A Bisanz; K Reyna; P Stanford; J E Lee; D B Evans Journal: Ann Surg Oncol Date: 2000-08 Impact factor: 5.344
Authors: Skye C Mayo; Andrew D Shore; Hari Nathan; Barish Edil; Christopher L Wolfgang; Kenzo Hirose; Joseph Herman; Richard D Schulick; Michael A Choti; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2010-09-08 Impact factor: 3.452
Authors: Deepthi M Reddy; Courtney M Townsend; Yong-Fang Kuo; Jean L Freeman; James S Goodwin; Taylor S Riall Journal: J Gastrointest Surg Date: 2009-09-16 Impact factor: 3.452
Authors: P A Baltodano; Y Webb-Vargas; K C Soares; C W Hicks; C M Cooney; P Cornell; K K Burce; T M Pawlik; F E Eckhauser Journal: Hernia Date: 2015-08-19 Impact factor: 4.739
Authors: Donald J Lucas; Adil Haider; Elliot Haut; Rebecca Dodson; Christopher L Wolfgang; Nita Ahuja; John Sweeney; Timothy M Pawlik Journal: Ann Surg Date: 2013-09 Impact factor: 12.969
Authors: Arja Gerritsen; Roos A W Wennink; Marc G H Besselink; Hjalmar C van Santvoort; Dorine S J Tseng; Elles Steenhagen; Inne H M Borel Rinkes; I Quintus Molenaar Journal: HPB (Oxford) Date: 2013-12-06 Impact factor: 3.647
Authors: Gaya Spolverato; Hadia Maqsood; Alessandro Vitale; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; T Clark Gamblin; Carlo Pulitano; Todd W Bauer; Feng Shen; George Poultsides; Shishir Maithel; J Wallis Marsh; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2015-04-23 Impact factor: 3.452
Authors: Dimitrios Xourafas; Katiuscha Merath; Gaya Spolverato; Stanley W Ashley; Jordan M Cloyd; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2018-07-23 Impact factor: 3.452
Authors: Donald J Lucas; Katherine I Schexneider; Matthew Weiss; Christopher L Wolfgang; Steven M Frank; Kenzo Hirose; Nita Ahuja; Martin Makary; John L Cameron; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2013-12-10 Impact factor: 3.452
Authors: Dimitrios Xourafas; Akweley Ablorh; Thomas E Clancy; Richard S Swanson; Stanley W Ashley Journal: J Gastrointest Surg Date: 2016-03-08 Impact factor: 3.452
Authors: Javier Valero-Elizondo; Yuhree Kim; Jason D Prescott; Georgios A Margonis; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2015-08-19 Impact factor: 3.452